References of "American Journal of Kidney Diseases"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNewer GFR Estimating Equations Require Validation in Different Populations
DELANAYE, Pierre ULiege; Ebert, N; Pottel, Hans

in American Journal of Kidney Diseases (2017), 70(4), 586

Detailed reference viewed: 49 (5 ULiège)
Full Text
Peer Reviewed
See detailConcordance between Iothalamate and Iohexol Plasma Clearance
DELANAYE, Pierre ULiege; LE GOFF, Caroline ULiege; JOURET, François ULiege et al

in American Journal of Kidney Diseases (2016), 68(2), 329-330

Detailed reference viewed: 21 (7 ULiège)
Full Text
Peer Reviewed
See detailConcordance between iohexol and iothalamate plasma clearance
DELANAYE, Pierre ULiege; JOURET, François ULiege; LE GOFF, Caroline ULiege et al

in American Journal of Kidney Diseases (2016)

Detailed reference viewed: 54 (6 ULiège)
Full Text
Peer Reviewed
See detailTerminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri, Fadi; Hourmant, Maryvonne; Campistol, Josep M. et al

in American Journal of Kidney Diseases (2016), 68(1), 84-93

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end ... [more ▼]

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end-organ damage. Eculizumab, a terminal complement inhibitor approved for aHUS treatment, was reported to improve hematologic and renal parameters in 2 prior prospective phase 2 studies. This is the largest prospective study of eculizumab in aHUS to date, conducted in an adult population. STUDY DESIGN: Open-label single-arm phase 2 trial. SETTING & PARTICIPANTS: Patients 18 years or older with aHUS (platelet count <150 x 10(3)/muL, hemoglobin </= lower limit of normal, lactate dehydrogenase >/=1.5 x upper limit of normal [ULN], and serum creatinine >/= ULN) were included in this multicenter multinational study. INTERVENTION: Intravenous eculizumab (900mg/wk for 4 weeks, 1,200mg at week 5 and then every 2 weeks) for 26 weeks. OUTCOMES & MEASUREMENTS: Primary end point was complete TMA response within 26 weeks, defined as hematologic normalization (platelet count >/=150 x 10(3)/muL, LDH </= ULN), and preservation of kidney function (<25% serum creatinine increase from baseline), confirmed by 2 or more consecutive measurements obtained 4 or more weeks apart. RESULTS: 41 patients were treated; 38 (93%) completed 26 weeks of treatment. 30 (73%) were included during their first TMA manifestation. 30 (73%) had complete TMA response. Platelet counts and estimated glomerular filtration rates increased from baseline (P<0.001). All 35 patients on baseline plasma exchange/plasma infusion discontinued by week 26. Of 24 patients requiring baseline dialysis, 5 recovered kidney function before eculizumab initiation and 15 of the remaining 19 (79%) discontinued dialysis during eculizumab treatment. No patients lost existing transplants. Quality-of-life measures were significantly improved. Two patients developed meningococcal infections; both recovered, and 1 remained on eculizumab treatment. LIMITATIONS: Single-arm open-label design. CONCLUSIONS: Results highlight the benefits of eculizumab in adult patients with aHUS: improvement in hematologic, renal, and quality-of-life parameters; dialysis discontinuation; and transplant protection. [less ▲]

Detailed reference viewed: 62 (0 ULiège)
Full Text
Peer Reviewed
See detailOnco-Nephrology: Core Curriculum 2015
Cohen, Eric; Krzesinski, Jean-Marie ULiege; Launay-Vacher, Vincent et al

in American Journal of Kidney Diseases (2015), 66(5), 869-883

The overlap between oncology and nephrology is an area of growing importance. A major reason for this is that less than half the patients with cancer were long-term survivors years ago, whereas now more ... [more ▼]

The overlap between oncology and nephrology is an area of growing importance. A major reason for this is that less than half the patients with cancer were long-term survivors years ago, whereas now more than two-thirds will live 5 years or longer. Late effects of cancer treatment include nephrotoxicity and are part of current clinical practice. In addition, cancer is now a known feature of chronic kidney disease (CKD), with increased risk in patients receiving dialysis or with a functioning kidney transplant, as well as those with earlier stages of the disease. Therefore, oncologists will refer patients to nephrologists, and nephrologists will need to consult oncologists. This Core Curriculum addresses the key issues at this challenging clinical interface. [less ▲]

Detailed reference viewed: 94 (6 ULiège)
Full Text
Peer Reviewed
See detailThe myth of the future burden of CKD in United States.
DELANAYE, Pierre ULiege; El-Nahas, M; Glassock, RJ

in American Journal of Kidney Diseases (2015), 66(1), 171-172

Detailed reference viewed: 55 (1 ULiège)
Full Text
Peer Reviewed
See detailSafety of living kidney donation: another brick in the wall…and a solid (physiologic) one.
DELANAYE, Pierre ULiege; Mariat, C; Glassock, RJ

in American Journal of Kidney Diseases (2015), 66(1), 1-3

Detailed reference viewed: 41 (1 ULiège)
Full Text
Peer Reviewed
See detailCreatinine-based GFR estimating equations in kidney transplant recipients
DELANAYE, Pierre ULiege

in American Journal of Kidney Diseases (2014), 64(5), 818

Detailed reference viewed: 42 (2 ULiège)
Full Text
Peer Reviewed
See detailGFR Estimation Using Standardized Cystatin C in Kidney Transplant Recipients
Masson, Ingrid; Maillard, Nicolas; Tack, Ivan et al

in American Journal of Kidney Diseases (2013), 61(2), 279-284

Background: The utility of serum cystatin C (SCysC) as a filtration marker in kidney transplantation is uncertain. We took advantage of the recent validation of a reference calibrator for SCysC and of ... [more ▼]

Background: The utility of serum cystatin C (SCysC) as a filtration marker in kidney transplantation is uncertain. We took advantage of the recent validation of a reference calibrator for SCysC and of newly developed CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations (2012) expressed for use with standardized SCysC level to reassess the performance of SCysC as a filtration marker in kidney transplant recipients. Study Design: Study of diagnostic test accuracy. Setting & Participants: 670 kidney transplant recipients from 3 centers undergoing glomerular filtration rate (GFR) measurements from December 2006 to November 2012. Index Test: Estimated GFR (eGFR) using the 2012 SCysC-based and serum creatinine (SCr)/SCysCbased CKD-EPI equations (eGFRcys and eGFRcr-cys, respectively) and the 2009 SCr-based CKD-EPI equation (eGFRcr), with SCysC and SCr measured at a single laboratory between April 2011 and June 2011. Reference Test: Measured GFR (mGFR) using urinary clearance of inulin. Results: Bias (the difference between mGFR and eGFR) was significantly smaller for eGFRcys and eGFRcr-cys versus eGFRcr ( 2.82 and 0.54 vs 4.4 mL/min/1.73 m2, respectively; P 0.001). Precision (standard deviation of the mean bias) also was better for eGFRcys and eGFRcr-cys versus eGFRcr (12 and 11 vs 13 mL/min/1.73 m2 [P 0.001 for both comparisons]). Accuracy (percentage of GFR estimates within 30% of mGFR) was greater for eGFRcys and eGFRcr-cys versus eGFRcr (81% and 86% vs 75%, respectively [P 0.004 and P 0.001]). Net reclassification index with respect to mGFR of 30 mL/min/1.73 m2 for eGFRcr-cys and eGFRcys versus eGFRcr was 18.8% [95% CI, 8.6%-28.9%] and 22.5% [95% CI, 10.2%-34.9%]. Limitations: Patients were exclusively of European descent; association with transplant outcome was not evaluated. Conclusions: Our data validate the use of both the newly developed SCysC-based and SCr/SCysC-based CKD-EPI equations (2012) in kidney transplant recipients. Both equations perform better than the SCr-based CKD-EPI equation (2009). [less ▲]

Detailed reference viewed: 43 (8 ULiège)
Full Text
Peer Reviewed
See detailAnorexia Nervosa and the Kidney
BOUQUEGNEAU, Antoine ULiege; DUBOIS, Bernard ULiege; Krzesinski, Jean-Marie ULiege et al

in American Journal of Kidney Diseases (2012), 60(2), 299-307

Anorexia nervosa is a common psychiatric disorder that disproportionately affects adolescents and young adults and is associated with high rates of morbidity and mortality. Anorexia nervosa can affect the ... [more ▼]

Anorexia nervosa is a common psychiatric disorder that disproportionately affects adolescents and young adults and is associated with high rates of morbidity and mortality. Anorexia nervosa can affect the kidney in numerous ways, including increased rates of acute kidney injury and chronic kidney disease, electrolyte abnormalities, and nephrolithiasis. Additionally, the diagnosis and treatment of anorexia nervosa–associated kidney diseases are challenging, reflecting complications such as refeeding syndrome, as well as the limitations of serum creatinine level in this population to estimate kidney function and the psychosocial challenges inherent with treating systemic manifestations of psychiatric conditions. In this review, we discuss kidney diseases and kidney-associated conditions that occur in individuals with anorexia nervosa, summarizing many of the challenges in treating patients with this disease [less ▲]

Detailed reference viewed: 46 (14 ULiège)
Full Text
Peer Reviewed
See detailAcute tubular dysfunction wtih Fanconi syndrome : a new manifestation of mitochondrial cytopathies
Debray, François-Guillaume ULiege; Merouani, A.; Lambert, M. et al

in American Journal of Kidney Diseases (2008), 51(4), 691-696

Detailed reference viewed: 33 (0 ULiège)
Full Text
Peer Reviewed
See detailCreatinine calibration in NHANES: is a revised MDRD study formula needed?
Delanaye, Pierre ULiege; Cavalier, Etienne ULiege; Maillard, Nicolas et al

in American Journal of Kidney Diseases (2008), 51(4), 709709-10

Detailed reference viewed: 42 (2 ULiège)